Evidence map›Paper›PMID 38082180›Full record

ArticleNature biomedical engineering2024

Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity.

Yining Zhu, Jingyao Ma, Ruochen Shen, Jinghan Lin, Shuyi Li, Xiaoya Lu, Jessica L Stelzel, Jiayuan Kong, Leonardo Cheng, Ivan Vuong and 20 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 96 citations in OpenAlex.

  1. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Article
  3. NNature · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. mRNA vaccines for gastrointestinal cancers: a paradigm shift in treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  20. Metabolic Checkpoints in CD8International journal of biological sciences · 2026
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 3 institutions in 1 country.

Yining ZhuDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jingyao MaInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Ruochen ShenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jinghan LinDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shuyi LiInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Xiaoya LuInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Jessica L StelzelDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-5644-9240
Jiayuan KongInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Leonardo ChengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ivan VuongDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3946-4772
Zhi-Cheng YaoInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Christine WeiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicole M KorinetzInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Wu Han TohInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Joseph ChoyInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6282-9437
Rebekah A ReynoldsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Melanie J ShearsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Won June ChoInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.
Natalie K LivingstonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gregory P HowardDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yizong HuDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3983-5104
Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Donald J ZackDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jordan J GreenDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4176-3808
Lei ZhengDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center and the Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4163-2541
Joshua C DoloffDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4323-3264
Jonathan P SchneckInstitute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-5346-2776
Sashank K ReddyDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sean C MurphyDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. murphysc@uw.edu.ORCID http://orcid.org/0000-0002-2048-0131
Hai-Quan MaoDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. hmao@jhu.edu.ORCID http://orcid.org/0000-0002-4262-9988
Johns Hopkins University · USBloomberg (United States) · USUniversity of Washington · US

Funding

TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JONATHAN P SCHNECK · 2019 to 2026
$11.5M
BIOMEDICAL ENGINEERING TRAINING PROGRAMT32GM007057 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI KANOLD, PATRICK O, KARCHIN, RACHEL · 1985 to 2023
$10.4M
Development of an oral liver-targeted prime-and-trap malaria vaccineU01AI155313 · NIAID · UNIVERSITY OF WASHINGTON · PI MURPHY, SEAN C · 2021 to 2025
$4.1M
NIAID NIH HHS U01 AI155313NIBIB NIH HHS P41 EB028239NIGMS NIH HHS T32 GM007057U.S. Department of Health & Human Services | National Institutes of Health (NIH) P41EB028239U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U01AI155313
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) can be designed to potentiate cancer immunotherapy by promoting their uptake by antigen-presenting cells, stimulating the maturation of these cells and modulating the activity of adjuvants. Here we report an LNP-screening method for the optimization of the type of helper lipid and of lipid-component ratios to enhance the delivery of tumour-antigen-encoding mRNA to dendritic cells and their immune-activation profile towards enhanced antitumour activity. The method involves screening for LNPs that enhance the maturation of bone-marrow-derived dendritic cells and antigen presentation in vitro, followed by assessing immune activation and tumour-growth suppression in a mouse model of melanoma after subcutaneous or intramuscular delivery of the LNPs. We found that the most potent antitumour activity, especially when combined with immune checkpoint inhibitors, resulted from a coordinated attack by T cells and NK cells, triggered by LNPs that elicited strong immune activity in both type-1 and type-2 T helper cells. Our findings highlight the importance of optimizing the LNP composition of mRNA-based cancer vaccines to tailor antigen-specific immune-activation profiles.

Indexed as

Dendritic CellsMice, Inbred C57BLNanoparticlesT-Lymphocytes, Helper-InducerAnimalsAntigens, NeoplasmCancer VaccinesFemaleImmunotherapyLipidsLiposomesMelanoma, ExperimentalMiceRNA, MessengerAntigens, NeoplasmCancer VaccinesLipid NanoparticlesLipidsLiposomesRNA, Messenger

Identifiers

PMID38082180
PMCPMC11162325
OpenAlexW4389564127

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.